Inspired by the untapped potential of non-model organism biology, the principals of Fauna Bio are leveraging insights from mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans. The Fauna Bio team are developing new ways to treat various human diseases - from heart disease and neurodegenerative disease - by addressing how to adopt /adapt mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists having intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bio is leveraging data from hundreds of species to enable development of pre-clinical and early clinical testing for new therapeutics targeting human diseases. With the principals having developed the world's largest biobank of animals with specialized adaptations, cutting-edge computational and genomics tools, Fauna Bio is structured around changing the paradigm of drug discovery and identifying novel drug targets across a broad range of clinical applications, from cardiovascular disease to Alzheimers.
